Description: IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Home Page: igcpharma.com
10224 Falls Road
Potomac,
MD
20854
United States
Phone:
301 983 0998
Officers
| Name | Title |
|---|---|
| Mr. Ram Mukunda | President, CEO & Director |
| Ms. Claudia Grimaldi | VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director |
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Mr. Rohit Goel | Senior Director of Accounting & Principal Accounting Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.6896 |
| Price-to-Sales TTM: | 25.0376 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 67 |